The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus
References
- WHO. Cardiovascular diseases (CVDs). Fact sheets [Internet]. 2021 [cited 2023 Jun 27]. Available from:
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) - Lindh M, Banefelt J, Fox KM, Hallberg S, Tai MH, Eriksson M, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: Estimates from Swedish population-based register data. European Heart Journal: Quality Care and Clinical Outcomes. 2019;5(3):225–232. DOI: 10.1093/ehjqcco/qcy058
- Toppila I, Ukkola-Vuoti L, Perttilä J, Törnwall O, Sinisalo J, Hartikainen J, et al. Cardiovascular event rate and death in high-risk secondary prevention patient cohort in Finland: A registry study. Clinical Cardiology. 2022;45(4):342–51. DOI: 10.1002/clc.23814
- Visseren FLJ, MacH F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–3337. DOI: 10.1093/eurheartj/ehab484
- Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720–3826. DOI: 10.1093/eurheartj/ehad191
- Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer cardiovascular polypill: A polypill for secondary cardiovascular prevention. International Journal of Cardiology. 2015;201(Suppl.):S15–S23. DOI: 10.1016/S0167-5273(15)31028-7
- Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill strategy in secondary cardiovascular prevention. The New England Journal of Medicine. 2022;387(11):967–977. DOI: 10.1056/NEJMoa2208275
- Ojji DB, Huffman MD. The place of polypill in secondary prevention of stroke. The Lancet Global Health. 2023;11(10):e1488–e1489. DOI: 10.1016/S2214-109X(23)00407-2
- World Health Organization (WHO). World Health Organization model list of essential medicines – 23rd list, 2023 [Internet]. Geneva; 2023. Available from:
https://www.phri.ca/wp-content/uploads/2023/07/WHO-MHP-HPS-EML-2023.02-eng.pdf - Laranjo L, Lanas F, Sun MC, Imran TF, Komiyama M, Kuwabara M, et al. World Heart Federation roadmap for secondary prevention of cardiovascular disease: 2023 update. Global Heart. 2024;19(1):
8 . DOI: 10.5334/gh.1278 - González-Juanatey JR, Cordero A, Castellano JM, Masana L, Dalmau R, Ruiz E, et al. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study. International Journal of Cardiology. 2022;361:116–123. DOI: 10.1016/j.ijcard.2022.05.015
- Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: Results from the FOCUS project. Journal of the American College of Cardiology. 2014;64(20):2071–2082. DOI: 10.1016/j.jacc.2014.08.021
- Gómez-Álvarez E, Verdejo J, Ocampo S, Ponte-Negretti CI, Ruíz E, Ríos MM. The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico. International Journal of Cardiology: Hear & Vasculature. 2020;29:
100545 . DOI: 10.1016/j.ijcha.2020.100545 - Castellano JM, Verdejo J, Ocampo S, Rios MM, Gómez-Álvarez E, Borrayo G, et al. Clinical effectiveness of the cardiovascular polypill in a real-life setting in patients with cardiovascular risk: The SORS study. Archives of Medical Research. 2019;50(1):31–40. DOI: 10.1016/j.arcmed.2019.04.001
- Gómez-Álvarez E, Verdejo J, Ocampo S, Ruiz E, Martinez-Rios MA. Reaching blood pressure guideline targets with the CNIC polypill in patients with a previous cardiovascular event in Mexico: A post hoc analysis of the SORS study. Future Cardiology. 2019;16(1):53–60. DOI: 10.2217/fca-2019-0075
- Grigorian-Shamagian L, Coca A, Morais J, Perez-Martinez P. The use of the CNIC-polypill in real-life clinical practice: Opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – Expert panel meeting report. BMC Proceedings. 2023;17(Suppl 8):
20 . DOI: 10.1186/s12919-023-00279-6 - Memon RA, Raveena Bai B, Simran F, Kumari M, Aisha F, Sai Kiran K, et al. Effect of the polypill on adherence and prevention of cardiovascular diseases in patients with or at high risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. Cureus. 2023;15(1):
e34134 . DOI: 10.7759/cureus.34134 - Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419–1423. DOI: 10.1136/bmj.326.7404.1419
- González-Juanatey JR, Tamargo J, Torres F, Weisser B, Oudovenko N. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Revista Española de Cardiología (English Ed). 2021;74(1):51–58. DOI: 10.1016/j.rec.2019.11.008
- Piepoli MF, Corrà U, Dendale P, Frederix I, Prescott E, Schmid JP, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. European Journal of Preventive Cardiology. 2016;23(18):1994–2006. DOI: 10.1177/2047487316663873
- Di Martino M, Alagna M, Lallo A, Gilmore KJ, Francesconi P, Profili F, et al. Chronic polytherapy after myocardial infarction: The trade-off between hospital and community-based providers in determining adherence to medication. BMC Cardiovascular Disorders. 2021;21(1):
180 . DOI: 10.1186/s12872-021-01969-9 - Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Associa. Journal of Hypertension. 2023;41(12):1874–2071. DOI: 10.1097/HJH.0000000000003480
- Muth C, Blom JW, Smith SM, Johnell K, Gonzalez-Gonzalez AI, Nguyen TS, et al. Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: A systematic guideline review and expert consensus. Journal of Internal Medicine. 2019;285(3):272–288. DOI: 10.1111/joim.12842
- Coca A, Kreutz R, Manolis AJ, Mancia G. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. Journal of Hypertension. 2020;38(10):1890–1898. DOI: 10.1097/HJH.0000000000002464
- Ros-Castelló V, Natera-Villalba E, Gómez-López A, Sánchez-Sánchez A, Chico-García JL, García-Madrona S, et al. Use of the cardiovascular polypill in secondary prevention of cerebrovascular disease: A real-life tertiary hospital cohort study of 104 patients. Cerebrovascular Disease Extra. 2020;10(3):166–173. DOI: 10.1159/000511064
- Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. Stroke [Internet]. 2021;52(7):e364–e467. DOI: 10.1161/STR.0000000000000375
- Dennison Himmelfarb CR, Beckie TM, Allen LA, Commodore-Mensah Y, Davidson PM, Lin G, et al. Shared decision-making and cardiovascular health: A scientific statement from the American Heart Association. Circulation. 2023;148(11):912–931. DOI: 10.1161/CIR.0000000000001162
- Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet [Internet]. 2017;389(10073):1055–1065. DOI: 10.1016/S0140-6736(17)30553-6
- Agarwal A, Huffman MD. Inclusion of polypills for prevention of cardiovascular disease in the 23rd World Health Organization model list of essential medicines: A significant step towards reducing global cardiovascular morbidity and mortality. Global Heart. 2024;19(1):
24 . DOI: 10.5334/gh.1310 - Webster R, Castellano JM, Onuma OK. Putting polypills into practice: Challenges and lessons learned. Lancet. 2017;389(10073):1066–1074. DOI: 10.1016/S0140-6736(17)30558-5
- Lin JK, Moran AE, Bibbins-Domingo K, Falase B, Pedroza Tobias A, Mandke CN, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: A modelling study. The Lancet Global Health. 2019;7(10):e1346–e1358. DOI: 10.1016/S2214-109X(19)30339-0
- Singh K, Crossan C, Laba TL, Roy A, Hayes A, Salam A, et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. International Journal of Cardiology. 2018;262:71–78. DOI: 10.1016/j.ijcard.2018.03.082
- Perrone-Filardi P, Minghetti P, Menditto E, Bianchi S, Scaglione F, Trifirò G, et al. The value of the polypill in cardiovascular disease: An Italian multidisciplinary Delphi panel consensus. Journal of Cardiovascular Medicine (Hagerstown). 2021;22(4):246–258. DOI: 10.2459/JCM.0000000000001159
- Becerra V, Gracia A, Desai K, Abogunrin S, Brand S, Chapman R, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5(5):
e0077111 . DOI: 10.1136/bmjopen-2014-007111 - Aguiar C, Araujo F, Rubio-Mercade G, Carcedo D, Paz S, Castellano JM, et al. Cost-Effectiveness of the CNIC-polypill strategy compared with separate monocomponents in secondary prevention of cardiovascular and cerebrovascular disease in Portugal: The MERCURY Study. Journal of Health Economics and Outcomes Research. 2022;9(2):134–146. DOI: 10.36469/jheor.2022.39768
- Gaziano T, Castellano JM, Dymond A, Looby A, Mealing S, Owen R, et al. Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: An analysis based on the SECURE trial. The Lancet Regional Health – Europe [Internet]. 2025;55:
101348 . DOI: 10.1016/j.lanepe.2025.101348 - Sepanlou SG, Mousavi SF, Poustchi H, Malekzadeh F, Roshandel G, Malekzadeh R. Reducing premature mortality from cardiovascular diseases in low and middle income countries: The role of Polypill in public health policy. International Journal of Cardiology Cardiovascular Risk and Prevention [Internet]. 2025;25(February):
200400 . DOI: 10.1016/j.ijcrp.2025.200400 - Cordero A, Gonzalez-Juanatey JR, Castellano JM, Masana L, Dalmau R, Ruiz Olivar JE, et al. The real-world cost and health resource utilization associated to the CNIC-polypill compared to usual care. European Heart Journal. 2021;42(Suppl. 1):
ehab724.2545 . DOI: 10.1093/eurheartj/ehab724.2545 - Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to cardiovascular disease and hypertension medicines in developing countries: An analysis of essential medicine lists, price, availability, and affordability. Journal of the American Heart Association. 2020;9(9):
e015302 . DOI: 10.1161/JAHA.119.015302 - Sethi Y, Biondi-Zoccai G. Unmet needs in cardiovascular disease care: An umbrella review of challenges, innovations, and systemic barriers. Minerva Cardiology and Angiology. 2025. DOI: 10.23736/S2724-5683.25.06853-X
- Harrison MA, Marfo AFA, Annan A, Ankrah DNA. Access to cardiovascular medicines in low- and middle-income countries: a mini review. Global Health Research and Policy. 2023;8. DOI: 10.1186/s41256-023-00301-6
- Abimbola S, Liu H. Adoption and scale-up of the cardiovascular Polypill: A realist institutional analysis. Health Policy and Planning. 2023;38(1):15–27. DOI: 10.1093/heapol/czac088
DOI: https://doi.org/10.5334/gh.1466 | Journal eISSN: 2211-8179
Language: English
Submitted on: Apr 25, 2025
Accepted on: Aug 26, 2025
Published on: Sep 24, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2025 Daniel Piñeiro, José Ramón González-Juanatey, Ana Abreu, Enrique Gómez Alvarez, Carlos Ponte-Negretti, Burkhard Weisser, Alexander Parkhomenko, Francisco Araújo, Alvaro Sosa-Liprandi, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.